Clinical Trial Detail

NCT ID NCT03362060
Title PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

triple-receptor negative breast cancer

Therapies

Pembrolizumab + PVX-410

Age Groups: adult senior

No variant requirements are available.